2.O'neill RE, Cao X. Co-Stimulatory and co-inhibitory pathways in cancer immunotherapy. Adv Cancer Res (2019) 143:145–94. 3.Schütz F, Stefanovic S, Mayer L, Von Au A, Domschke C, Sohn C. PD-1/ PD-L1 pathway in breast cancer...
PD-1/PD-L1 免疫药物在肿瘤的治疗中确实发挥了重要的作用,其机制主要阻断 PD-1 和 PD-L1 之间的相互作用,可以显著增强免疫功能,抑制肿瘤生长。 根据新型抗肿瘤药物临床应用指导原则,肺癌 PD-1/PD-L1 治疗药物有 7 种,患者在使用时需要临床医生充分评估患者病情后,并根据患者的经济条件合理选择最合适的免疫药物...
PD1/PD-L1通路在肿瘤免疫逃逸中的作用机制主要包括以下几个方面:(1)PD1/PD-L1通路可诱导肿瘤特异性T淋巴细胞凋亡:肿瘤细胞表达的PD-L1与活化T细胞表面的PD1结合诱导活化T细胞凋亡,阻断PD1/PD-L1信号通路能减少肿瘤特异性T细胞凋亡【11】;(2)PD1/PD-L1通路可制T淋巴细胞的增殖分化:PD1/PD-L1信号活化可以抑制RAS/...
目前 , PD-1/PD-L1信号通路抑制剂已进入临床试验阶段 , 并且在治疗多种实体瘤中具有良好的疗效和安全性 。关键词 PD-1/PD-L1信号通路 ; 实体瘤 ; 研究进展 中图分类号 R73文献标识码 A文章编号 1673-7210(2015 0 6、4(a -0047-04Research progress of PD-1/PD-L1pathway in solid tumorsSHI ...
本文就目前在TNBC患者中以PD-1、PD-L1抑制剂为基础的联合治疗进行总结,以期为TNBC患者临床治疗提供参考。 关键词: 三阴性乳腺癌;免疫疗法;程序性细胞死亡蛋白1抑制剂;程序性细胞死亡配体1抑制剂;联合治疗 ABSTRACT Breast cancer ranks first among female malignant tumors, while triple-negative breast cancer (...
The programmed cell death-1 receptor (PD-1) is an immune checkpoint inhibitor which is expressed on the surface of immune effector cells. It is activated mainly by PD-L1 which can be expressed by all human cells. The PD-1/PD-L1 pathway plays a subtle role in maintaining peripheral T-lym...
结论:PD-L1和PD-1在前列腺癌中的高表达与患者局部或远处转移密切相关,可能参与了前列腺癌的免疫逃逸。 【关键词】前列腺癌,PD-L1,PD-1 Expressions and Clinical Significance of PD-L1 and PD-1 in Prostate Cancer Minbo Yan1, Wenfei Lian1, Shuchang Huang1, Wenjie Cheng1, Jing Lu2*, Yingbo Dai1...
[ 摘要 ]程序性细胞死亡受体 1(PD-1) 和程序性细胞死亡配体 1(PD-L1) 靶向治疗作为一种新型免疫疗法,改变了许多癌症的治疗格局,但仅有部分患者可从免疫治疗中获益,其影响因素之一是肿瘤 PD-1/PD-L1 的表达水平。如何实现对其无...
Results The expression of PD-1 and PD-L1 in CRC was significantly (P<0.05) higher than that in normal tissues, which were highly positively correlated with each other (P<0.001). The expression of PD-L1 in cancer nests was significantly correlated with age(P<0.01). and which in tumor ...
[4] Luke JJ, Ott PA. PD-1 pathwayinhibitors: the next Generation of immunotherapy for advanced melanoma[J]. Oncotarget,2015, 6(6):3479-3492. [5] Garon EB, Rizvi NA, Hui R, et al.Pembrolizumab for the treat-ment of non-small-cell lung cancer[J]. N EnglJ Med, 2015, 372 (21)...